NAM
ALXN

Nissay Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Nissay Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,045
Closed -$4.42M – 770
2021
Q2 		$4.42M Buy
24,045
+1,118
+5% +$192K 0.04% 262
2021
Q1 		$3.51M Sell
22,927
-523
-2% -$80.9K 0.03% 295
2020
Q4 		$3.66M Sell
23,450
-162
-0.7% -$20.8K 0.06% 265
2020
Q3 		$2.7M Sell
23,612
-5,893
-20% -$636K 0.05% 299
2020
Q2 		$3.31M Buy
29,505
+1,220
+4% +$130K 0.06% 269
2020
Q1 		$2.54M Buy
28,285
+654
+2% +$64.2K 0.06% 275
2019
Q4 		$2.99M Buy
27,631
+494
+2% +$52.8K 0.07% 308
2019
Q3 		$2.66M Buy
27,137
+1,235
+5% +$139K 0.07% 321
2019
Q2 		$3.39M Sell
25,902
-927
-3% -$119K 0.09% 261
2019
Q1 		$3.63M Sell
26,829
-692
-3% -$86K 0.1% 248
2018
Q4 		$2.68M Buy
27,521
+619
+2% +$73.2K 0.08% 289
2018
Q3 		$3.74M Buy
26,902
+624
+2% +$78.3K 0.1% 248
2018
Q2 		$3.26M Sell
26,278
-608
-2% -$71.1K 0.1% 256
2018
Q1 		$3M Buy
26,886
+547
+2% +$65.4K 0.09% 264
2017
Q4 		$3.15M Buy
+26,339
New +$3.21M 0.1% 262

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Nissay Asset Management's ALXN Position: Q3 2021 in Review

Nissay Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 24,045 shares — an estimated $4.42M sold.

Nissay Asset Management first reported a position in ALXN in Q4 2017 and held it in 15 quarters. The position peaked at $4.42M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Nissay Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Nissay Asset Management sold 24,045 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.42M.
  • Nissay Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Nissay Asset Management's Alexion Pharmaceuticals position peaked at $4.42M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Nissay Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.